{
  "trial_id": "NCT01525589",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, BRCA1/2 mutation status, HER-2 status, number of prior chemotherapy regimens, prior trastuzumab treatment, organ function (liver, kidney, hematological, metabolic, cardiac), prior radiotherapy, prior hormonal therapy, prior biological/investigational therapy, ongoing toxicity from prior therapy, child-bearing potential and contraception use, prior treatment with PARP inhibitors, presence of brain metastases, presence of bone metastases, history of cardiac disease, breathing difficulties, active infection status, wound healing status, viral hepatitis status, HIV status, muscular disease status, pregnancy status, breastfeeding status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "BRCA deleterious mutation",
          "BRCA1/2 mutation status"
        ],
        [
          "Sites of disease at diagnosis",
          "presence of brain metastases"
        ],
        [
          "Prior radiotherapy",
          "prior radiotherapy"
        ],
        [
          "Prior hormonal therapy",
          "prior hormonal therapy"
        ],
        [
          "Prior biological/investigational therapy",
          "prior biological/investigational therapy"
        ],
        [
          "Prior treatment with PARP inhibitors",
          "prior treatment with PARP inhibitors"
        ],
        [
          "Stage at diagnosis",
          "number of prior chemotherapy regimens"
        ],
        [
          "Histology type at diagnosis",
          "HER-2 status"
        ],
        [
          "ECOG PS",
          "ongoing toxicity from prior therapy"
        ],
        [
          "Hormonal status",
          "child-bearing potential and contraception use"
        ],
        [
          "Sites at baseline",
          "presence of bone metastases"
        ],
        [
          "History of cardiac disease",
          "history of cardiac disease"
        ],
        [
          "Moderate breathing difficulties or oxygen requirement",
          "breathing difficulties"
        ],
        [
          "Active uncontrolled infection",
          "active infection status"
        ],
        [
          "Unhealed wound or presence of any external drainage",
          "wound healing status"
        ],
        [
          "Chronically active viral hepatitis",
          "viral hepatitis status"
        ],
        [
          "Immunocompromised patients, including those known to be infected by human immunodeficiency virus (HIV)",
          "HIV status"
        ],
        [
          "Known muscular disease or functional alteration",
          "muscular disease status"
        ],
        [
          "Pregnant or breastfeeding women",
          "pregnancy status"
        ],
        [
          "Pregnant or breastfeeding women",
          "breastfeeding status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Race/Ethnicity",
        "Region of Enrollment",
        "Histology grade at diagnosis",
        "Weight",
        "Height",
        "Body Surface Area",
        "Albumin",
        "Number of sites at baseline",
        "Time from first diagnosis to registration",
        "Time from metastatic disease to registration",
        "Time from last progression before study entry"
      ],
      "remaining_candidate_features": [
        "organ function (liver, kidney, hematological, metabolic, cardiac)"
      ]
    },
    "processed-gen-response": "Age, gender, BRCA1/2 mutation status, HER-2 status, number of prior chemotherapy regimens, prior trastuzumab treatment, organ function (liver, kidney, hematological, metabolic, cardiac), prior radiotherapy, prior hormonal therapy, prior biological/investigational therapy, ongoing toxicity from prior therapy, child-bearing potential and contraception use, prior treatment with PARP inhibitors, presence of brain metastases, presence of bone metastases, history of cardiac disease, breathing difficulties, active infection status, wound healing status, viral hepatitis status, HIV status, muscular disease status, pregnancy status, breastfeeding status."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Race/Ethnicity, Customized, Region of Enrollment, BRCA1/2 mutation status, HER-2 status, Number of prior chemotherapy regimens, Organ function (liver, kidney, hematological, metabolic, cardiac), Prior treatment with PARP inhibitors, Prior radiotherapy, Prior hormonal therapy, Prior biological/investigational therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "BRCA deleterious mutation",
          "BRCA1/2 mutation status"
        ],
        [
          "Prior radiotherapy",
          "Prior radiotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "ECOG PS",
        "Sites of disease at diagnosis",
        "Histology type at diagnosis",
        "Histology grade at diagnosis",
        "Stage at diagnosis",
        "Hormonal status",
        "Sites at baseline",
        "Prior surgery",
        "Weight",
        "Height",
        "Body Surface Area",
        "Albumin",
        "Number of sites at baseline",
        "Time from first diagnosis to registration",
        "Time from metastatic disease to registration",
        "Time from last progression before study entry"
      ],
      "remaining_candidate_features": [
        "HER-2 status",
        "Number of prior chemotherapy regimens",
        "Organ function (liver, kidney, hematological, metabolic, cardiac)",
        "Prior treatment with PARP inhibitors",
        "Prior hormonal therapy",
        "Prior biological/investigational therapy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Race/Ethnicity, Region of Enrollment, BRCA1/2 mutation status, HER-2 status, Number of prior chemotherapy regimens, Organ function (liver, kidney, hematological, metabolic, cardiac), Prior treatment with PARP inhibitors, Prior radiotherapy, Prior hormonal therapy, Prior biological/investigational therapy"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Eastern Cooperative Oncology Group (ECOG) Performance Status, Region of Enrollment, Body Mass Index, Prior Chemotherapy Regimens, Prior Trastuzumab-containing Regimen, Prior Radiotherapy, Prior Hormonal Therapy, Prior Biological/Investigational Therapy, Known Deleterious Germline Mutation of BRCA1/2, Prior Treatment with PARP Inhibitors.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "ECOG PS",
          "Eastern Cooperative Oncology Group (ECOG) Performance Status"
        ],
        [
          "BRCA deleterious mutation",
          "Known Deleterious Germline Mutation of BRCA1/2"
        ],
        [
          "Prior radiotherapy",
          "Prior Radiotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Race/Ethnicity",
        "Sites of disease at diagnosis",
        "Histology type at diagnosis",
        "Histology grade at diagnosis",
        "Stage at diagnosis",
        "Hormonal status",
        "Sites at baseline",
        "Prior surgery",
        "Weight",
        "Height",
        "Body Surface Area",
        "Albumin",
        "Number of sites at baseline",
        "Time from first diagnosis to registration",
        "Time from metastatic disease to registration",
        "Time from last progression before study entry"
      ],
      "remaining_candidate_features": [
        "Body Mass Index",
        "Prior Chemotherapy Regimens",
        "Prior Trastuzumab-containing Regimen",
        "Prior Hormonal Therapy",
        "Prior Biological/Investigational Therapy",
        "Prior Treatment with PARP Inhibitors."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Eastern Cooperative Oncology Group (ECOG) Performance Status, Region of Enrollment, Body Mass Index, Prior Chemotherapy Regimens, Prior Trastuzumab-containing Regimen, Prior Radiotherapy, Prior Hormonal Therapy, Prior Biological/Investigational Therapy, Known Deleterious Germline Mutation of BRCA1/2, Prior Treatment with PARP Inhibitors."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, prior chemotherapy regimens, prior trastuzumab-containing regimens, disease duration, number of metastatic sites, presence of visceral metastases, presence of bone metastases, presence of brain metastases, BRCA 1/2 mutation status, HER-2 status, hormone receptor status, prior hormonal therapy, prior biological/investigational therapy, prior radiotherapy, presence of ongoing toxicity, presence of comorbidities (e.g., cardiac disease, chronic viral hepatitis, immunocompromised status).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "ECOG PS",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ],
        [
          "BRCA deleterious mutation",
          "BRCA 1/2 mutation status"
        ],
        [
          "Hormonal status",
          "hormone receptor status"
        ],
        [
          "Prior radiotherapy",
          "prior radiotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment",
        "Sites of disease at diagnosis",
        "Histology type at diagnosis",
        "Histology grade at diagnosis",
        "Stage at diagnosis",
        "Sites at baseline",
        "Prior surgery",
        "Weight",
        "Height",
        "Body Surface Area",
        "Albumin",
        "Number of sites at baseline",
        "Time from first diagnosis to registration",
        "Time from metastatic disease to registration",
        "Time from last progression before study entry"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "body mass index (BMI)",
        "prior chemotherapy regimens",
        "prior trastuzumab-containing regimens",
        "disease duration",
        "number of metastatic sites",
        "presence of visceral metastases",
        "presence of bone metastases",
        "presence of brain metastases",
        "HER-2 status",
        "prior hormonal therapy",
        "prior biological/investigational therapy",
        "presence of ongoing toxicity",
        "presence of comorbidities (e.g., cardiac disease, chronic viral hepatitis, immunocompromised status)"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, prior chemotherapy regimens, prior trastuzumab-containing regimens, disease duration, number of metastatic sites, presence of visceral metastases, presence of bone metastases, presence of brain metastases, BRCA 1/2 mutation status, HER-2 status, hormone receptor status, prior hormonal therapy, prior biological/investigational therapy, prior radiotherapy, presence of ongoing toxicity, presence of comorbidities (e.g., cardiac disease, chronic viral hepatitis, immunocompromised status)."
  }
}